Skip to main
HAE

Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics (HAE) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 38%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Haemonetics is expected to continue growing in their core Plasma segment, has a Buy rating and $96 price target, and recently received FDA approvals for new products. They are undergoing a restructuring and have two main business units, Apheresis and MedSurg, with potential for growth through mergers and acquisitions. However, competition and potential impacts on demand for their products may pose risks to their rating and price target.

Bears say

Haemonetics is facing challenges in meeting their guidance and long-term financial targets due to increased operating spend and potential tariff impacts, leading to a below-midpoint revenue estimate for FY2027. While the company has potential for growth with new products and potential M&A in the high-growth MedTech industry and strong brand reputation, risks such as competition, procedure volumes, and potential treatments could impact demand for their products. Despite potential growth opportunities, the negative outlook is driven by uncertainties and risks that could impact the company's financial performance and hinder its ability to meet its targets.

Haemonetics (HAE) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 38% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Haemonetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Haemonetics (HAE) Forecast

Analysts have given Haemonetics (HAE) a Buy based on their latest research and market trends.

According to 8 analysts, Haemonetics (HAE) has a Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $88.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $88.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Haemonetics (HAE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.